Recent Updates
Recently added Catalysts
BBIO Positive Sentiment Score: 75/100

BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023

Friday, July 14, 2023 1 min read
Key Takeaway: BridgeBio Pharma is set to host an investor call on July 17, 2023, to present topline results from the Phase 3 ATTRibute-CM study, which focuses on transthyretin amyloid cardiomyopathy. This event signifies the company's commitment to communication with investors and stakeholders regarding its developments in genetic diseases. The results shared during this call are anticipated to provide valuable insights into the effectiveness of their treatment in the study's patient population.

Market Sentiment Analysis

POSITIVE FACTORS

  • BridgeBio will share topline results, indicating progress in research.
  • The investor call highlights transparency and engagement with stakeholders.

Full Press Release Details

PALO ALTO, Calif., July 14, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will host an investor call on Monday, July 17 at 8:00 am ET to share topline results from the Phase 3 ATTRibute-CM clinical study in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
To access the live webcast, please visit the “Events” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.
About BridgeBio Pharma, Inc.
contact@bridgebio.com

Frequently Asked Questions

When is the investor call for BridgeBio Pharma scheduled?

The investor call is on July 17, 2023, at 8:00 am ET.

What study's results will be discussed in the call?

The call will share topline results from the Phase 3 ATTRibute-CM study.

How can I access the live webcast of the investor call?

Visit the ‘Events’ page in the Investors section of the BridgeBio website.

Will there be a replay available for the webcast?

Yes, a replay will be available for 90 days after the event.

What focus does BridgeBio Pharma have?

BridgeBio focuses on genetic diseases and cancers.

Tags: BBIO Viatris Investor Conferences Healthcare BridgeBio ATTR-CM clinical study investor call biopharmaceutical
Last updated: Jul 14, 2023